ACRS vs. NLTX, XOMA, VNDA, CRMD, NATR, XERS, RVNC, MRSN, ADCT, and INZY
Should you be buying Aclaris Therapeutics stock or one of its competitors? The main competitors of Aclaris Therapeutics include Neoleukin Therapeutics (NLTX), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), CorMedix (CRMD), Nature's Sunshine Products (NATR), Xeris Biopharma (XERS), Revance Therapeutics (RVNC), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), and Inozyme Pharma (INZY). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Aclaris Therapeutics has a consensus target price of $22.25, indicating a potential upside of 2,060.19%. Given Neoleukin Therapeutics' higher possible upside, analysts plainly believe Aclaris Therapeutics is more favorable than Neoleukin Therapeutics.
Neoleukin Therapeutics has higher earnings, but lower revenue than Aclaris Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Aclaris Therapeutics had 6 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 6 mentions for Aclaris Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 1.01 beat Aclaris Therapeutics' score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.
Neoleukin Therapeutics has a net margin of 0.00% compared to Neoleukin Therapeutics' net margin of -248.28%. Aclaris Therapeutics' return on equity of -37.22% beat Neoleukin Therapeutics' return on equity.
Aclaris Therapeutics received 327 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 66.96% of users gave Aclaris Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Aclaris Therapeutics has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
52.4% of Neoleukin Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are held by institutional investors. 1.6% of Neoleukin Therapeutics shares are held by insiders. Comparatively, 6.4% of Aclaris Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Aclaris Therapeutics beats Neoleukin Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Aclaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclaris Therapeutics Competitors List
Related Companies and Tools
